[The current status of genetic testing for leukemia]

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Context:

• Pathogenic chromosome translocations in hematological malignancies create fusion genes.
• Reverse transcription-polymerase chain reaction (RT-PCR) is a key detection method.
• Minimal residual disease (MRD) detection is vital for leukemia management.

Purpose:

• To highlight the importance of RT-PCR for detecting fusion genes and MRD in leukemia.
• To discuss the significance of quantitative MRD analysis for treatment efficacy and prognosis.
• To address the lack of standardized laboratory procedures and associated challenges in genetic testing for leukemia.

Summary:

• RT-PCR detects leukemia-associated fusion genes and minimal residual disease (MRD), offering higher sensitivity than morphological testing.
• Quantitative MRD analysis is essential for evaluating treatment effectiveness and predicting leukemia recurrence.
• Mutation analysis guides therapeutic strategies for imatinib-resistant cases and stratifies acute myeloid leukemia treatment.

Impact:

• Establishes MRD detection as critical for leukemia diagnosis, prognosis, and monitoring.
• Emphasizes the need for standardized genetic testing protocols to improve accuracy and reliability.
• Informs therapeutic decisions and treatment stratification in hematological malignancies.